Sign up USA
Proactive Investors - Run By Investors For Investors

Aethlon Medical soars after FDA fast-tracks its virus treatment device

The FDA fast-track program was established to speed up patient access to breakthrough technologies with the potential to address life threatening diseases for which no approved treatment alternatives exist
Blood sample
The Hemopurifier is a single-use device indicated for the treatment of life-threatening viruses

Shares in Aethlon Medical Inc (NASDAQ:AEMD) soared as the therapeutic technology company received a green light from the US Food and Drug Administration (FDA).

The shares rose 70% to US$3.39 after the company said the FDA had issued an Expedited Access Pathway (EAP) designation to support the advancement of Aethlon’s Hemopurifier device to treat life-threatening viruses.

The designation means the device will be fast-tracked through the regulatory process.

The Hemopurifier is a single-use device indicated for the treatment of life-threatening viruses that are not addressed with an approved treatment.

To date, the Hemopurifier has been validated The FDA approved Aethlon’s “indicated for use” application, meaning that rather than be used for a single disease condition, it can be used to capture a broad-spectrum of viruses, including life-threatening strains of pandemic influenza viruses, mosquito-borne viruses as well as haemorrhagic viruses that are not addressed with an approved treatment.

View full AEMD profile View Profile

Related Articles

Paradigm Biopharmaceuticals: Access latest PPT from Proactive's CEO Sessions
May 18 2017
Paul Rennie talked timeline to clinical trial results with investors.
eye-766166_1280_583251a48f148.jpg
November 20 2016
The flagship product, CardioCel, is a bio-engineered tissue scaffold used in the heart valve repair market.
Clinical Trial
August 04 2017
The study, codenamed INTEREST, should be wrapped up in the fourth-quarter
Copyright © Proactiveinvestors.com, 2017. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use